Premium
[P1–212]: CEREBROSPINAL FLUID LEVELS OF ANGIOTENSIN‐CONVERTING ENZYME ARE ASSOCIATED WITH AMYLOID‐β IN ALZHEIMER's DISEASE
Author(s) -
Rocha Natalia P.,
Toledo Andre ASF.,
Corgosinho Laiane TS.,
Cruz de Souza Leonardo,
Paula França Resende Elisa,
Braz Nayara FT.,
Simoes e Silva Ana C.,
Caramelli Paulo,
Teixeira Antonio L.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.032
Subject(s) - cerebrospinal fluid , biomarker , lumbar puncture , medicine , angiotensin converting enzyme , renin–angiotensin system , neurology , central nervous system , alzheimer's disease , endocrinology , disease , blood pressure , psychiatry , chemistry , biochemistry
have investigated the role of trans-acting factors; transcription factor SOX2 and miRNA-140, in ADAM10 gene regulation. The entire sequence of ADAM10 gene is analyzed by computational bioinformatics and screened for probable trans-actors with high regulatory importance. Results: Our study shows that miRNA-140-5p has enhanced expression in AD post-mortem brain hippocampus using high throughput micro-arrays and qRT-PCR. Interestingly we have also seen that miRNA-140 seed sequence is present on both ADAM10 and SOX2 3’UTR and thus reporter constructs containing regulatory elements were transfected into human cell lines along with miRNA-140 mimics and inhibitors to evaluate their interaction by dual luciferase reporter assays. The specific interaction of miRNA-140 with both ADAM10 and its transcription factor SOX2 signifies high regulatory importance of this miRNA in controlling ADAM10 expression.Conclusions:Thus our proposed investigation unravels the mechanisms underlying ADAM10 downregulation bymiR-140 that exacerbates Alzheimer’s disease related neurotoxic effects. Our findings could reflect a strong basis for future research aimed at understanding the potential contribution of trans-acting factors as a biomarker or modulator of AD pathophysiology.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom